Expertise in
2
conditions

Signe Friesland

Neck, 
Stockholm, AB, SE 
Expertise in
2
conditions
Neck, 
Stockholm, AB, SE 

Overview

Signe Friesland practices practicing medicine in Stockholm, Sweden.

Ms. Friesland is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Adenoid Cystic Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, and Lung Cancer.

She is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Neck, Stockholm, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.
A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.
Enrollment Status: Completed
Publish Date: September 02, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

53 Total Publications

Radiotherapy with or without concurrent cetuximab in HPV-positive oropharyngeal squamous cell carcinoma - A pooled analysis from two ARTSCAN trials.
Radiotherapy with or without concurrent cetuximab in HPV-positive oropharyngeal squamous cell carcinoma - A pooled analysis from two ARTSCAN trials.
Journal: Clinical and translational radiation oncology
Published: March 31, 2026

Frequently Asked Questions about Signe Friesland

Is Signe Friesland a top-rated expert for Adenoid Cystic Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Signe Friesland is classified as an Advanced expert for Adenoid Cystic Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Signe Friesland participate in research or clinical trials?

Yes. Signe Friesland has published 53 articles and abstracts on conditions like Adenoid Cystic Carcinoma. You can view a list of Signe Friesland's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Friesland's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile